Interpretation of the Pituitary Society International Consensus of Diagnosis and Management of Prolactin-Secreting Pituitary Adenomas
10.3760/cma.j.cn311282-20240129-00047
- VernacularTitle:《垂体催乳素腺瘤的诊断和治疗——垂体学会国际共识声明》解读
- Author:
Lijin JI
1
;
Bin LU
;
Hongying YE
;
Yiming LI
Author Information
1. 复旦大学附属华山医院内分泌科，上海 200040
- Keywords:
Hyperprolactinemia;
Prolactin-secreting adenoma;
Dopamine agonist;
Surgery
- From:
Chinese Journal of Endocrinology and Metabolism
2024;40(5):365-372
- CountryChina
- Language:Chinese
-
Abstract:
The Pituitary Society released the 2023 International Consensus on the Diagnosis and Treatment of Prolactin-Secreting Adenomas, marking another update following the guidelines from the Endocrine Society in 2006 and 2011. Published in Nature Reviews Endocrinology, this consensus is based on the latest research evidence in recent years, covering topics such as the efficacy, long-term adverse effects, and withdrawal protocols of dopamine receptor agonists, as well as indications for surgery, preoperative medical therapy, and radiation therapy. It comprehensively discusses the treatment of prolactin-secreting adenomas in special periods and conditions. This article provides a detailed interpretation of the core recommended points in the consensus, focusing on four major aspects: diagnosis, treatment, special populations, and rare conditions of prolactinoma, aiming to help clinicians gain a comprehensive understanding of the consensus and provide assistance in clinical management.
